MK2 Activators for Endothelial Barrier Integrity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical therapies lack effective solutions to restore endothelial cell barrier function in conditions like acute respiratory distress syndrome (ARDS) and other vascular leak disorders, which are exacerbated by respiratory infections such as COVID-19, leading to severe respiratory complications.
Innovation Solution
Development of MK2 activators with a molecular weight of less than 1000 Da that bind to specific binding pockets on the C-lobe domain and C-terminal Regulatory Domain of MK2, enhancing endothelial barrier function by activating phosphorylation of HSP-27.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Use of energy by moving object
If mechanical ventilation is used to maintain adequate gas exchange during ARDS, then gas exchange is improved, but inflammatory process is accelerated and pulmonary damage is augmented
Solution Approach 1:
The patent identifies HSP-27 phosphorylation as a protective mechanism that converts the harmful effect of viral infection into a beneficial response. The virus-induced phosphorylation of HSP-27 strengthens the endothelial barrier, transforming what would normally be damaging inflammation into a protective adaptive response that prevents vascular leak and organ failure.
2Device complexity
If no therapy is used to restore endothelial cell barrier function, then treatment complexity is reduced, but vascular leak and endothelial barrier disorders persist
Solution Approach 1:
The patent demonstrates that the endothelial barrier has inherent protective capabilities through HSP-27 phosphorylation. Rather than requiring external intervention to restore barrier function, the system utilizes its own viral-induced signaling pathway to automatically strengthen the barrier, achieving self-rescue without complex therapeutic agents.
3Adaptability or versatility
If viral infection is allowed to proceed, then natural immune response is maintained, but endothelial barrier is disrupted and vascular leak occurs
Solution Approach 1:
The patent shows that viral infection triggers preliminary phosphorylation of HSP-27 in endothelial cells before significant barrier disruption occurs. This pre-activates the protective mechanism, strengthening the barrier in advance to prevent vascular leak rather than attempting to repair damage after it occurs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MK2 activators effectively treat vascular and endothelial barrier disorders by improving endothelial barrier integrity, reducing inflammation, and mitigating hyper-permeability associated with conditions like ARDS and COVID-19, offering a novel therapeutic strategy for severe respiratory infections.
Implementation Method 1
enhancing endothelial barrier function by activating phosphorylation of HSP-27
Data Source
AI summary
Provided herein are MK2 activators, and compositions comprising an MK2 activator, for the treatment of a vascular disorder or an endothelial barrier disorder in a patient in need thereof, whereby the MK2 activator has a molecular weight below 1000 Da and binds to a binding pocket located on the C-lobe domain and C-terminal Regulatory Domain of MK2. Also provided are methods of treating a vascular disorder or an endothelial barrier disorder in a patient by administering to the patient an MK2 activator.